Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Jun 26, 2014)
  • 8-K (Jun 25, 2014)
  • 8-K (Jun 11, 2014)
  • 8-K (Jun 5, 2014)
  • 8-K (Jun 2, 2014)
  • 8-K (May 22, 2014)

 
Other

Auxilium Pharmaceuticals 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Graphic
  4. Graphic

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported):  May 10, 2012

 

Auxilium Pharmaceuticals, Inc.

(Exact Name of Registrant Specified in Charter)

 

Delaware

(State or Other

Jurisdiction of

 Incorporation)

 

000-50855

(Commission File

Number)

 

23-3016883

(I.R.S. Employer

Identification No.)

 

40 Valley Stream Parkway

 

 

Malvern, PA

 

19355

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:   (484) 321-5900

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02                                             Results of Operations and Financial Condition.

 

On May 10, 2012, Auxilium Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2012. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 7.01                                             Regulation FD Disclosure.

 

As previously announced, the Company will conduct a conference call today, Thursday, May 10, 2012 at 10:00 a.m. ET to discuss results and highlights of the first quarter 2012.  The presentation slides to be used during the call will be available on the “For Investors” section of the Company’s web site (http://www.auxilium.com) under the “Presentations” tab beginning at 7 a.m. ET on Thursday, May 10, 2012.  An audio feed of the conference call will be simultaneously web cast on the Company’s web site and will be available, along with the presentation slides, on the “For Investors” section of the Auxilium web site under the “Events” tab beginning at 10:00 a.m. ET on Thursday, May 10, 2012, and will remain available for future review until June 10, 2012.

 

The information contained in, or that can be accessed through the Company’s web site, is not a part of this filing.

 

Item 9.01                                             Financial Statements and Exhibits

 

(d)                                  Exhibits.

 

The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be deemed to be “filed”:

 

99.1                           Press Release dated May 10, 2012 issued by Auxilium Pharmaceuticals, Inc.

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

AUXILIUM PHARMACEUTICALS, INC.

 

 

 

 

 

 

Date: May 10, 2012

 

By:

/s/ James E. Fickenscher

 

 

 

James E. Fickenscher

 

 

 

Chief Financial Officer

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description of Exhibit

 

 

 

99.1

 

Press Release dated May 10, 2012 issued by Auxilium Pharmaceuticals, Inc.

 

4


 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki